Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 129.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 137.50
  • 52 Week Low: 96.00
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 11,334
  • Market Cap: £135.16m
  • RiskGrade: 66

Tuesday broker round-up UPDATE

Date: Tuesday 04 Feb 2014

LONDON (ShareCast) - Alumasc: FinnCap ups target price from 142p to 167p and retains its buy recommendation.

Barratt Developments: Barclays increases target price from 444.7p to 471.2p and keeps an overweight rating.

Bellway: Barclays raises target price from 1498.1p to 1552.6p, but keeps an underweight rating.

Berkeley Group: Barclays ups target price from 2454.7p to 2561.5p, but downgrades to underweight.

Bovis Homes Group: Barclays increases target price from 778.1p to 807.3p, while keeping an underweight rating.

BP: Investec places its target price (prev.: 460p) under review keeping its hold recommendation.

Cello Group: N+1 Singer moves target price from 118p to 123p maintaining a buy recommendation.

Galliford Try: Barclays shifts target price from 1200.1p to 1207.7p and retains an equal-weight rating.

Kirkland Lake Gold: Investec reduces target price from 353p to 200p retaining its buy recommendation.

Land Securities: Barclays increases target price from 935p to 1246p and reiterates an overweight rating.

Low & Bonar: Numis moves target price from 85p to 95p, while downgrading from buy to add.

Pearson: Deutsche Bank reduces target price from 1000p to 960p keeping a sell recommendation.

Persimmon: Barclays raises target price from 1260.4p to 1333.6p and stays with its equal-weight rating.

Premier Farnell: Cantor Fitzgerald cuts target price from 275p to 250p, while its buy recommendation remains unchanged.

Quindell: Canaccord Genuity raises target price from 45p to 75p and stays with its buy recommendation.

Redrow: Barclays ups target price from 356p to 383.4p maintaining an overweight rating.

Renishaw: Investec raises target price from 1795p to 1940p upgrading from sell to hold.

Sainsbury: Bernstein upgrades to 'outperform', retains 4,300p target price.

Serco Group: Cantor Fitzgerald reduces target price from 460p to 365p and stays with its sell recommendation.

Smith & Nephew: Numis ups target price from 960p to 1000p and reiterates an add rating.

SSE: UBS lowers target price from 1560p to 1475p, while its buy recommendation is kept.

St Modwen Property: Numis ups target price from 401p to 441p and maintains an add rating.

Tate & Lyle: Numis shaves target price from 863p to 858p, while upgrading from hold to add.

Taylor Wimpey: Barclays increases target price from 146.8p to 156.5p and stays with its overweight rating.

Tesco: Macquarie cuts target price from 390p to 370p maintaining an outperform rating.

TUI Travel: Deutsche Bank ups target price from 360p to 395p and reiterates a hold recommendation.

UBM: Nomura lowers target price from 740p to 720p and reiterates a neutral rating.

UDG Healthcare: Jefferies ups target price from 340p to 385p and keeps a buy recommendation.

Victrex: Numis downgrades from add to hold with a target price of 1831p.

Walker Greenbank: Investec takes target price from 169p to 182p and retains a buy recommendation. WH Ireland moves target price from 185p to 195p maintaining its buy recommendation.

WPP Group: JP Morgan cuts target price from 1617p to 1583p, while leaving its overweight rating unaltered.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 129.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 137.50
52 Week Low 96.00
Volume 11,334
Shares Issued 104.77m
Market Cap £135.16m
RiskGrade 66

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.66% below the market average65.66% below the market average65.66% below the market average65.66% below the market average65.66% below the market average
82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average
Price Trend
42.45% above the market average42.45% above the market average42.45% above the market average42.45% above the market average42.45% above the market average
35.00% above the sector average35.00% above the sector average35.00% above the sector average35.00% above the sector average35.00% above the sector average
Income
13.66% above the market average13.66% above the market average13.66% above the market average13.66% above the market average13.66% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average
Growth
33.21% below the market average33.21% below the market average33.21% below the market average33.21% below the market average33.21% below the market average
41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 12-Nov-2019

Time Volume / Share Price
12:57 34 @ 130.00p
12:57 1,185 @ 130.00p
12:57 1,207 @ 130.00p
12:51 6,250 @ 128.72p
11:00 38 @ 128.69p

Cello Health Key Personnel

CEO Mark Scott

Top of Page